Xiaojuan Chen, Xiaoning Liu, Fengjuan Li, Haitian He, Xinying Li, Tianhang Qin, Bin Jiang, Yuge Chen, Yanqi Wang, Yuhao Su, Xiaojie Wang, Lei Liang, Huiling Hua, Jun Wu, Jianping Ma, Fulan Hu, Pei Qin
{"title":"Depression and health outcomes: An umbrella review of systematic reviews and meta-analyses of observational studies.","authors":"Xiaojuan Chen, Xiaoning Liu, Fengjuan Li, Haitian He, Xinying Li, Tianhang Qin, Bin Jiang, Yuge Chen, Yanqi Wang, Yuhao Su, Xiaojie Wang, Lei Liang, Huiling Hua, Jun Wu, Jianping Ma, Fulan Hu, Pei Qin","doi":"10.1038/s41398-025-03463-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Currently, most studies of depression are limited to a single disease endpoint.</p><p><strong>Aims: </strong>This study aimed to conduct an umbrella review to comprehensively assess the association between depression and health outcomes.</p><p><strong>Method: </strong>Until December 17, 2024, we conducted a systematic search of systematic reviews and meta-analyses in PubMed, Embase, and Web of Science. We reanalyzed the summary effects and 95% confidence intervals for each study using random models. We assessed the methodological quality and evidence quality of the research with A Measurement Tool to Assess Systematic Reviews 2 and Grade of Recommendations, Assessment, Development and Evaluation, classifying studies into four categories based on evidence classification criteria.</p><p><strong>Results: </strong>We selected a total of 72 articles from 27,150 resulting in 114 meta-analyses and 109 health outcomes. Depression exposure was associated with 23 mortality, 21 cardiovascular outcomes, 15 offspring outcomes, 9cancer outcomes, 9 neurological outcomes, 5 endocrine outcomes, 5 dental outcomes, 3 digestive outcomes, and 19 other health outcomes. Moderate-quality evidence linked depression to specific mortality in bladder cancer (Class IV), all-cause mortality in myocardial infarction (Class III), mortality within 2 years of initial assessment in coronary artery disease (Class IV), major adverse cardiovascular events after percutaneous coronary intervention (Class III), irritable bowel syndrome (insignificant), fear of falling (Class III), and frailty (Class III).</p><p><strong>Conclusions: </strong>Depression has a significant impact on health outcomes, primarily mortality and cardiovascular outcomes. However, more definitive conclusions still require randomized controlled trials or prospective studies for validation.</p>","PeriodicalId":23278,"journal":{"name":"Translational Psychiatry","volume":"15 1","pages":"298"},"PeriodicalIF":6.2000,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12368087/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41398-025-03463-8","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Currently, most studies of depression are limited to a single disease endpoint.
Aims: This study aimed to conduct an umbrella review to comprehensively assess the association between depression and health outcomes.
Method: Until December 17, 2024, we conducted a systematic search of systematic reviews and meta-analyses in PubMed, Embase, and Web of Science. We reanalyzed the summary effects and 95% confidence intervals for each study using random models. We assessed the methodological quality and evidence quality of the research with A Measurement Tool to Assess Systematic Reviews 2 and Grade of Recommendations, Assessment, Development and Evaluation, classifying studies into four categories based on evidence classification criteria.
Results: We selected a total of 72 articles from 27,150 resulting in 114 meta-analyses and 109 health outcomes. Depression exposure was associated with 23 mortality, 21 cardiovascular outcomes, 15 offspring outcomes, 9cancer outcomes, 9 neurological outcomes, 5 endocrine outcomes, 5 dental outcomes, 3 digestive outcomes, and 19 other health outcomes. Moderate-quality evidence linked depression to specific mortality in bladder cancer (Class IV), all-cause mortality in myocardial infarction (Class III), mortality within 2 years of initial assessment in coronary artery disease (Class IV), major adverse cardiovascular events after percutaneous coronary intervention (Class III), irritable bowel syndrome (insignificant), fear of falling (Class III), and frailty (Class III).
Conclusions: Depression has a significant impact on health outcomes, primarily mortality and cardiovascular outcomes. However, more definitive conclusions still require randomized controlled trials or prospective studies for validation.
背景:目前,大多数关于抑郁症的研究都局限于单一的疾病终点。目的:本研究旨在进行一项全面的综述,以全面评估抑郁症与健康结果之间的关系。方法:截至2024年12月17日,我们在PubMed、Embase和Web of Science中进行了系统综述和meta分析的系统检索。我们使用随机模型重新分析了每个研究的总结效应和95%置信区间。我们使用A Measurement Tool to Assessment Systematic Reviews 2和Grade of Recommendations, Assessment, Development and Evaluation来评估研究的方法质量和证据质量,并根据证据分类标准将研究分为四类。结果:我们从27,150篇文章中共选择了72篇,包括114项荟萃分析和109项健康结果。抑郁症暴露与23例死亡率、21例心血管预后、15例后代预后、9例癌症预后、9例神经预后、5例内分泌预后、5例牙齿预后、3例消化预后和19例其他健康预后相关。中等质量的证据表明,抑郁症与膀胱癌的特定死亡率(IV类)、心肌梗死的全因死亡率(III类)、冠状动脉疾病初始评估后2年内的死亡率(IV类)、经皮冠状动脉介入治疗后的主要不良心血管事件(III类)、肠易激动综合征(无关重要)、害怕跌倒(III类)和虚弱(III类)有关。结论:抑郁对健康结局,主要是死亡率和心血管结局有显著影响。然而,更明确的结论仍需要随机对照试验或前瞻性研究来验证。
期刊介绍:
Psychiatry has suffered tremendously by the limited translational pipeline. Nobel laureate Julius Axelrod''s discovery in 1961 of monoamine reuptake by pre-synaptic neurons still forms the basis of contemporary antidepressant treatment. There is a grievous gap between the explosion of knowledge in neuroscience and conceptually novel treatments for our patients. Translational Psychiatry bridges this gap by fostering and highlighting the pathway from discovery to clinical applications, healthcare and global health. We view translation broadly as the full spectrum of work that marks the pathway from discovery to global health, inclusive. The steps of translation that are within the scope of Translational Psychiatry include (i) fundamental discovery, (ii) bench to bedside, (iii) bedside to clinical applications (clinical trials), (iv) translation to policy and health care guidelines, (v) assessment of health policy and usage, and (vi) global health. All areas of medical research, including — but not restricted to — molecular biology, genetics, pharmacology, imaging and epidemiology are welcome as they contribute to enhance the field of translational psychiatry.